Do Mineralocorticoid Receptor Antagonists Suppress Atrial Fibrillation/Flutter?

Naccarelli et al. (Mon,) studied this question.

www.synapsesocial.com/papers/69f961a1752e510096648ae9 — DOI: https://doi.org/10.1016/j.jacc.2021.04.080

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes· 2021 · 138 citations
2. Valsartan for Prevention of Recurrent Atrial Fibrillation· 2009 · 442 citations
3. The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling· 2019 · 65 citations
4. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus· 2020 · 444 citations
5. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes· 2020 · 2,559 citations